Khair Abdulhafeez M
Department of Pediatrics, Division of Pediatric Neurology, Hamad Medical Corporation, Doha, Qatar.
Neurol Res Int. 2016;2016:7685807. doi: 10.1155/2016/7685807. Epub 2016 Apr 28.
Autoimmune-mediated encephalopathy in children continues to constitute a diagnostic and therapeutic challenge in pediatric population. Utility and usefulness in this clinical setting of plasmapheresis have seldom been evaluated in current pediatric literature. Children with immune-mediated encephalopathies represent a uniquely different group among patients presenting to intensive care units or neurological services worldwide. Arriving at a final diagnosis is not an easy task for treating physicians. It is very crucial to consider early use of first-line immunotherapy modalities, save those children's lives and improve outcomes. Plasmapheresis is an emerging, potentially beneficial first-line therapy in such patients. However, indications, value, logistics, and procedural difficulties are often faced. This study is mainly meant to review the current knowledge in regard to the clinical value of plasmapheresis in children with immune-mediated encephalopathy.
儿童自身免疫介导的脑病在儿科人群中仍然是一个诊断和治疗难题。目前儿科文献中很少评估血浆置换在这种临床情况下的实用性和有效性。免疫介导性脑病患儿在全球重症监护病房或神经科就诊的患者中是一个独特的不同群体。对于治疗医生来说，做出最终诊断并非易事。考虑早期使用一线免疫治疗方法、挽救这些儿童的生命并改善预后至关重要。血浆置换是这类患者中一种新兴的、可能有益的一线治疗方法。然而，常常会面临适应症、价值、后勤保障和操作困难等问题。本研究主要旨在回顾关于血浆置换在免疫介导性脑病患儿中的临床价值的现有知识。
